CHEMOMAB
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022.
CHEMOMAB
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.chemomab.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
80.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Euro
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Biotheus
Biotheus is a biotech company that focuses on the discovery and development of antibody-based therapeutics.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
I-Mab Biopharma
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
InventisBio
InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.
LYNK Pharmaceuticals
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Prothena
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-16 | Anchiano Therapeutics | Anchiano Therapeutics acquired by Chemomab | N/A |
Investors List
Presight Capital
Presight Capital investment in Post-IPO Equity - Chemomab
Apeiron Investment Group
Apeiron Investment Group investment in Post-IPO Equity - Chemomab
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - Chemomab
Peter Thiel
Peter Thiel investment in Post-IPO Equity - Chemomab
OrbiMed
OrbiMed investment in Post-IPO Equity - Chemomab
OrbiMed
OrbiMed investment in Series C - Chemomab
Presight Capital
Presight Capital investment in Series C - Chemomab
Thiel Capital
Thiel Capital investment in Series C - Chemomab
Peter Thiel
Peter Thiel investment in Series B - Chemomab
OrbiMed
OrbiMed investment in Series B - Chemomab
Key Employee Changes
Official Site Inspections
http://www.chemomab.com Semrush global rank: 7.1 M Semrush visits lastest month: 592
- Host name: 172.67.161.182
- IP address: 172.67.161.182
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Chemomab"
Chemomab - Crunchbase Company Profile & Funding
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high …See details»
About - Chemomab
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein …See details»
Chemomab Investor Relations - Overview
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and …See details»
Chemomab Org Chart + Executive Team - The Official Board
Organizational Chart of Chemomab. Chemomab Org Chart www.chemomab.com. has 13 executives +972 773 310 156; Add an executive. Chemomab (CMMB) News ... HR & …See details»
Chemomab - Org Chart, Teams, Culture & Jobs - The Org
Chemomab Therapeutics (NASDAQ: CMMB), is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases. Industries. Pharmaceutical. Headquarters. Tel Aviv …See details»
Chemomab - Contacts, Employees, Board Members, Advisors
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics. ... Experience the new Crunchbase, powered by AI . Experience the …See details»
ChemomAb Company Profile - Office Locations, Competitors
Oct 29, 2024 ChemomAb is a clinical stage biopharmaceutical company which develops therapeutic antibodies for the treatment of autoimmune and inflammatory diseases. The …See details»
Chemomab Therapeutics (CMMB) Company Profile & Description
6 days ago Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing …See details»
Chemomab Therapeutics - LinkedIn
Chemomab Therapeutics | 2,325 followers on LinkedIn. Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high unmet need | Chemomab is a …See details»
Chemomab Therapeutics Announces Executive Leadership …
Jun 5, 2023 About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases …See details»
Chemomab Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients …See details»
Chemomab Investor Relations - News
Mar 3, 2025 On February 19, 2025, Chemomab reported that the International Nonproprietary Names (INN) program of the World Health Organization had assigned the INN designation …See details»
Chemomab - Funding, Financials, Valuation & Investors
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics. New. Resources. Advanced Search. ... How much funding has this …See details»
Chemomab
Chemomab’s lead compound, CM-101, currently in Phase 2 clinical studies, is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity. CM-101 …See details»
Chemomab Reports New Positive Clinical Data at EASL 2025 …
1 day ago Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, “This new clinical data further confirms the potential of nebokitug (CM-101) as a first-in-class …See details»
Pioneering Innovative Treatments for Fibrotic Diseases
%PDF-1.7 %µµµµ 1 0 obj >/Metadata 2989 0 R/ViewerPreferences 2990 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI ...See details»
Chemomab Highlights New Data Supporting Lead Drug Candidate …
1 day ago Chemomab Therapeutics (NASDAQ: CMMB) unveiled new clinical results that they will present at the EASL 2025 Annual Congress on May 7-10, providing additional support for …See details»
Chemomab Reports New Positive Clinical Data at EASL 2025 …
2 days ago Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, commented, “This new clinical data further confirms the potential of nebokitug (CM-101) as a first-in-class …See details»
R&D — Chemomab
Chemomab's R&D talent, infrastructure and capabilities support early-stage discovery through clinical development. Our R&D team is investigating underlying fibro-inflammatory biology via a broad range of in-vitro and in-vivo models, which provide the foundation for development of potentially transformative patient therapeutics.See details»
Chemomab Completes Successful End-of-Phase 2 Meeting and …
Feb 19, 2025 Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role …See details»